Skip to Main Content

Author Details

Alan D D'Andrea
Dana-Farber Cancer Institute
1978
332
104
PMIDPaper TitleJournal TitlePublished Year
36202931Targeting replication stress in cancer therapy.Nat Rev Drug Discov2023
36202931Targeting replication stress in cancer therapy.Nat Rev Drug Discov2023
37951209Transforming ovarian cancer care by targeting minimal residual disease.Med2023
37665033Novobiocin blocks nucleic acid binding to Polθ and inhibits stimulation of its ATPase activity.Nucleic Acids Res2023
37819936A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.Clin Cancer Res2023
37985839STAG2 Regulates Homologous Recombination Repair and Sensitivity to ATM Inhibition.Adv Sci (Weinh)2023
37978141Targeting Polymerase Theta (POLθ) for Cancer Therapy.Cancer Treat Res2023
37707822Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial.JAMA Oncol2023
37696958Dynamics of the DYNLL1-MRE11 complex regulate DNA end resection and recruitment of Shieldin to DSBs.Nat Struct Mol Biol2023
37863027Fork restart: unloading FANCD2 to travel ahead.Mol Cell2023
37034578Dynamics of the DYNLL1/MRE11 complex regulates DNA end resection and recruitment of the Shieldin complex to DSBs.bioRxiv2023
36914658Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer.Nat Commun2023
37863027Fork restart: unloading FANCD2 to travel ahead.Mol Cell2023
37665033Novobiocin blocks nucleic acid binding to Polθ and inhibits stimulation of its ATPase activity.Nucleic Acids Res2023
37707822Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial.JAMA Oncol2023
37951209Transforming ovarian cancer care by targeting minimal residual disease.Med2023
37696958Dynamics of the DYNLL1-MRE11 complex regulate DNA end resection and recruitment of Shieldin to DSBs.Nat Struct Mol Biol2023
37985839STAG2 Regulates Homologous Recombination Repair and Sensitivity to ATM Inhibition.Adv Sci (Weinh)2023
37978141Targeting Polymerase Theta (POLθ) for Cancer Therapy.Cancer Treat Res2023
37819936A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.Clin Cancer Res2023
37034578Dynamics of the DYNLL1/MRE11 complex regulates DNA end resection and recruitment of the Shieldin complex to DSBs.bioRxiv2023
36914658Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer.Nat Commun2023
35149538Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.Clin Cancer Res2022
36251350An Accessible Communication System for Population-Based Genetic Testing: Development and Usability Study.JMIR Form Res2022
36044844CHAMP1 binds to REV7/FANCV and promotes homologous recombination repair.Cell Rep2022
35972384Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.Cancer Res2022
36155347Using Social Media to Facilitate Communication About Women's Testing: Tool Validation Study.JMIR Form Res2022
35500223Metformin for treatment of cytopenias in children and young adults with Fanconi anemia.Blood Adv2022
35552618Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer.Cancer Discov2022
36442094CCAR2 functions downstream of the Shieldin complex to promote double-strand break end-joining.Proc Natl Acad Sci U S A2022
36441774TGFβ pathway is required for viable gestation of Fanconi anemia embryos.PLoS Genet2022
35149709Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.Nat Commun2022
35149538Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.Clin Cancer Res2022
34887522Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.Br J Cancer2022
35500223Metformin for treatment of cytopenias in children and young adults with Fanconi anemia.Blood Adv2022
35552618Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer.Cancer Discov2022
36442094CCAR2 functions downstream of the Shieldin complex to promote double-strand break end-joining.Proc Natl Acad Sci U S A2022
36441774TGFβ pathway is required for viable gestation of Fanconi anemia embryos.PLoS Genet2022
36044844CHAMP1 binds to REV7/FANCV and promotes homologous recombination repair.Cell Rep2022
35972384Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.Cancer Res2022
36155347Using Social Media to Facilitate Communication About Women's Testing: Tool Validation Study.JMIR Form Res2022
36251350An Accessible Communication System for Population-Based Genetic Testing: Development and Usability Study.JMIR Form Res2022
34887522Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.Br J Cancer2022
35149709Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.Nat Commun2022
32997960MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia.Cell Stem Cell2021
34179826A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.Nat Cancer2021
34131002Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.Clin Cancer Res2021
34285063Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma.Clin Cancer Res2021
33883185Genomic Landscape of Primary and Recurrent Anal Squamous Cell Carcinomas in Relation to HPV Integration, Copy-Number Variation, and DNA Damage Response Genes.Mol Cancer Res2021
33514515Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in <i>TP53-</i> and <i>BRCA1</i>-Deficient Cells.Cancer Res2021
  • 1 - 50 of 664

Recommended Authors

Pavana Anur
Oregon Health & Science University
Career Start Year 2009
Number of shared co-authors 11
Jordi Carreras Puigvert
Department of Pharmaceutical Biosciences, Uppsala University
Career Start Year 2009
Number of shared co-authors 0
Srikanth Talluri
VA Boston Healthcare System
Career Start Year 2008
Number of shared co-authors 0
Georgia Velimezi
University of Patras
Career Start Year 2008
Number of shared co-authors 0
Francis P Lach
The Rockefeller University.
Career Start Year 2007
Number of shared co-authors 6
Joanna I Loizou
Center for Cancer Research, Comprehensive Cancer Centre, Medical University of Vienna
Career Start Year 2002
Number of shared co-authors 0
Tarek Abbas
University of Virginia
Career Start Year 2001
Number of shared co-authors 0
Kevin R Brown
College Street, University of Toronto
Career Start Year 2000
Number of shared co-authors 2
Junjie Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2000
Number of shared co-authors 6
Rachel Toth
University of Dundee
Career Start Year 1999
Number of shared co-authors 1
Thomas Helleday
The University of Sheffield
Career Start Year 1998
Number of shared co-authors 8
Aaron Aslanian
Salk Institute for Biological Studies
Career Start Year 1998
Number of shared co-authors 0
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 5
Sandra Burkett
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 1
Shiaw-Yih Lin
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 5
Daniel Durocher
The Lunenfeld-Tannenbaum Research Institute, Mount Sinai Hospital
Career Start Year 1995
Number of shared co-authors 8
James DeGregori
University of Colorado Anschutz Medical Campus
Career Start Year 1991
Number of shared co-authors 5
Alex Vassilev
National Institute of Child Health & Human Development, National Institutes of Health
Career Start Year 1991
Number of shared co-authors 0
Glenn S Cowley
Broad Institute of Harvard and MIT
Career Start Year 1990
Number of shared co-authors 19
Josephine C Dorsman
Cancer Center Amsterdam
Career Start Year 1988
Number of shared co-authors 2
Razqallah Hakem
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1987
Number of shared co-authors 3
Stephen P Jackson
Mission Therapeutics Ltd. Glenn Berge Building
Career Start Year 1987
Number of shared co-authors 5
Ralf Kittler
McDermott Center for Human Growth and Development.
Career Start Year 1984
Number of shared co-authors 4
Feyruz V Rassool
University of Maryland Greenebaum Comprehensive Cancer Center
Career Start Year 1984
Number of shared co-authors 1
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year 1982
Number of shared co-authors 29
Ashok R Venkitaraman
University of Cambridge, Hutchison Research Centre
Career Start Year 1982
Number of shared co-authors 3
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 4
Ze'ev Ronai
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 1981
Number of shared co-authors 5
J. Wade Harper
Harvard Medical School
Career Start Year 1981
Number of shared co-authors 13
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 11

Collaborators

Dipanjan Chowdhury
Dana-Farber Cancer Institute
Co-authored papers 17
David Kozono
Co-authored papers 13
Huy Nguyen
The University of Danang-University of Science and Technology
Co-authored papers 11
Clark C Chen
University of Minnesota
Co-authored papers 9
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 7
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 6
Christopher G Mathew
Co-authored papers 6
Steven P Gygi
Harvard Medical School
Co-authored papers 5
Jean Soulier
University of Paris
Co-authored papers 5
Peter K Sorger
Co-authored papers 5
Gerburg M Wulf
Co-authored papers 4
Atanas Kamburov
Broad Institute of Harvard and MIT
Co-authored papers 4
Eric P Winer
Dana-Farber Cancer Institute
Co-authored papers 4
Wilhelm Haas
Co-authored papers 4
Stephen J Elledge
Howard Hughes Medical Institute, Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 4
Judy E Garber
Dana-Farber Cancer Institute
Co-authored papers 4
John A Tainer
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Jaegil Kim
Co-authored papers 4
Simon J Boulton
The Francis Crick Institute
Co-authored papers 3
Paz Polak
McGill University
Co-authored papers 3
Laura J Niedernhofer
University of Minnesota
Co-authored papers 3
Alex Look
Dana-Farber Cancer Institute
Co-authored papers 3
Sandro Santagata
Co-authored papers 3
David M Weinstock
Merck & Co.
Co-authored papers 3
Michael S Lawrence
Co-authored papers 3
Webster K Cavenee
Ludwig Institute for Cancer Research, University of California San Diego
Co-authored papers 3
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 3
Douglas A Levine
Perlmutter Cancer Center
Co-authored papers 3
Peter J Park
Harvard Medical School
Co-authored papers 3
Lewis C Cantley
Co-authored papers 3
Release 1.2